Search

Your search keyword '"RAIMONDI, C."' showing total 431 results
Start Over Author "RAIMONDI, C."
431 results on '"RAIMONDI, C."'

101. Phospholipase C?1 is required for metastasis development and progression

Author

Sala, G., Dituri, F., Raimondi, C., Previdi, S., Maffucci, T., Mazzoletti, M., Rossi, C., Iezzi, M., Lattanzio, R., Piantelli, M., Iacobelli, S., Broggini, M., Falasca, Marco, Sala, G., Dituri, F., Raimondi, C., Previdi, S., Maffucci, T., Mazzoletti, M., Rossi, C., Iezzi, M., Lattanzio, R., Piantelli, M., Iacobelli, S., Broggini, M., and Falasca, Marco

Abstract

Cell motility and invasion play an essential role in the development of metastasis. Evidence suggests that the enzyme phospholipase C?1 (PLC?1) may be involved in tumor progression and possibly development of metastasis. In this study, we show that down-regulation of PLC?1 expression severely impairs activation of the small GTP-binding protein Rac and cell invasion in breast cancer cell lines and U87 in vitro. Experimental metastasis assays in nude mice show that inducible knockdown of PLC?1 strongly inhibits development of MDA-MB-231-derived lung metastasis and reverts metastasis formation. In addition, analysis of 60 breast cancer patients' tissues revealed an increase of PLC?1 expression in metastasis compared with the primary tumor in 50% of tissues analyzed. These data showa critical role of PLC?1 in the metastatic potential of cancer cells, and they further indicate that PLC?1 inhibition has a therapeutic potential in the treatment of metastasis dissemination. ©2008 American Association for Cancer Research.

Published
2008

115. Flow cytometry evaluation of urinary sediment in renal transplantation

Author

Nanni-Costa A, Iannelli S, Vangelista A, Andrea Buscaroli, Liviano G, Raimondi C, Todeschini P, Lamanna G, Stefoni S, and Bonomini V

Subjects
Transplantation, 030230 surgery, Urine, Flow Cytometry, Kidney Transplantation, Killer Cells, Natural, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Antigens, CD, Reference Values, Humans, 030211 gastroenterology & hepatology, Lymphocytes
Abstract

The value of exfoliative urinary cytology for the diagnosis of different pathological conditions in renal transplantation is widely recognized. The method, however, has not yet gained full acceptance, mainly because identification of the different cells is not always possible by means of standard staining techniques. In view of its characteristics, flow cytometry (FC) seems to represent a consistently reliable, rapid and innovative approach for differentialing the various cells present in the urinary sediment and assessing their number. This study gives the examination result of 223 urinary specimens from 127 transplanted patients selected according to pathology. Sediment cells, collected from fresh urine samples, were washed, treated with a lysing solution, resuspended in saline solution and directly analysed in a FACSCAN cytometer. Morphological evaluation showed: a small number of cells in patients with stable renal function; a larger number of cells, with predominance of lymphocytes, during acute rejection episodes; an absolute predominance of neutrophils during bacterial infection; large-sized cellular debris in cases of post-transplant tubular necrosis; and small cell debris in cases of cyclosporine cytotoxicity. Lymphocyte surface-marker evaluation made it possible to differentiate lymphocyte populations observed during acute rejection episodes (cytotoxic T-cell, CD8 and HLA class II and NK cells) from those detected during bacterial infection (T-cell CD4 positive). These results suggest that urinary FC may be a reliable diagnostic tool in clinical renal transplantation.

Published
1992

116. Intra- and Ost-dialysis 'Release' of PDGF-AB

Author

Cianciolo, G., Donati, G., De Pascalis, A., Manna, C., Iannelli, S., Coli, L., Raimondi, C., Dalmastri, V., Marseglia, C.D., Stefoni, S., Cianciolo, G., Donati, G., De Pascalis, A., Manna, C., Iannelli, S., Coli, L., Raimondi, C., Dalmastri, V., Marseglia, C.D., and Stefoni, S.

Abstract

No abstract, non disponibile

Published
2000

118. Cytokine Gene Polymorphisms and Breast Cancer Susceptibility

Author

SCOLA, L., primary, VAGLICA, M., additional, CRIVELLO, A., additional, PALMERI, L., additional, FORTE, G. I., additional, MACALUSO, M. C., additional, GIACALONE, A., additional, NOTO, L. D., additional, BONGIOVANNI, A., additional, RAIMONDI, C., additional, ACCARDO, A., additional, VERNA, R., additional, CANDORE, G., additional, CARUSO, C., additional, LIO, D., additional, and PALMERI, S., additional

Published
2006
Full Text
View/download PDF

126. “Release” Intra- E Ost- Dialitico Di PDGF-AB

Author

Cianciolo, G., primary, Donati, G., additional, De Pascalis, A., additional, Manna, C., additional, Iannelli, S., additional, Colì, L., additional, Raimondi, C., additional, Dalmastri, V., additional, Marseglia, C.D., additional, and Stefoni, S., additional

Published
2000
Full Text
View/download PDF

136. Standard Heparin versus Low-Molecular-Weight Heparin

Author

Stefoni, S., Cianciolo, G., Donati, G., Colì, L., Manna, G. La, Raimondi, C., Dalmastri, V., Orlandi, V., and D’Addio, F.

Abstract

AbstractBackground: To compare standard heparin (SH) and low molecular weight heparin (LMWH) in terms of anticoagulation, platelet activation and lipid metabolism, we selected 54 patients who had been on 4-hour hemodialysis three times weekly for at least 12 months, without bleeding disorders or dyslipidemic diseases. 28 were on hemodialysis with Polysulfone low-flux, 26 were on hemodiafiltration with Polysulfone high-flux. All patients underwent EPO. Methods: During the first 18 months, we administered SH 1,500 IU on starting dialysis and 1,500 ± 500 IU in continuous intradialytic infusion per session. In the following 18 months, we administered LMWH 64.6 IU/kg on starting dialysis in a single arterious bolus. We assessed aPTT, anti-factor Xa activity, TAT and FPA, β-TG and PF4. Blood samples were taken monthly at times 0, 30, 60, 180 and 240 min, as well as 1, 4 and 20 h after dialysis end. Predialysis cholesterol, HDL, LDL, triglycerides and lipoprotein(a) were checked monthly. Results: During both LMWH and SH sessions no clotting or major bleeding complications were observed. APTT with LMWH was lower than that found with SH (p < 0.001); aFXa using LMWH was higher than when using SH (p < 0.001); TAT and FPA were lower in LMWH sessions (p < 0.01) than in SH sessions. We also detected lower β-TG (p < 0.05) and PF4 levels (p < 0.05) using LMWH than using SH. As regards lipids, we only observed a significant decrease in triglycerides after 18 months of LMWH treatment. Conclusions: Routine use of LMWH during hemodialysis affords a safe and effective alternative to SH, and causes reduced platelet activation.Copyright © 2002 S. Karger AG, Basel

Published
2002

137. Intra- and post-dialytic platelet activation and PDGF-AB release: cellulose diacetate vs polysulfone membranes.

Author

Cianciolo, G, Stefoni, S, Donati, G, De Pascalis, A, Iannelli, S, Manna, C, Colì, L, Bertuzzi, V, La Manna, G, Raimondi, C, Boni, P, and Stefoni, V

Abstract

During haemodialysis the blood-membrane contact causes a release of platelet granule content, which contains platelet-derived growth factor AB (PDGF-AB). In view of the potential role of this in altering biocompatibility during haemodialysis, we evaluated the intra- and post-dialytic changes in PDGF-AB serum levels during haemodialysis sessions performed with cellulose diacetate (CDA) and polysulfone (PS) membranes respectively.

Published
2001
Full Text
View/download PDF

138. Levels and patterns of HIV RNA viral load in untreated pregnant women

Author

Patel, D, Thorne, C, Newell, Ml, CORTINA BORJA, M, Giaquinto, Carlo, Rampon, O, D'Elia, R, DE ROSSI, Anita, GROSCH WORNER, I, Mok, J, DE JOSE MI, Martinez, Bl, Pena, Jm, Garcia, Jg, Lopez, Jra, GARCIA RODRIGUEZ, J, ASENSI BOTET, F, Otero, Mc, PEREZ TAMARIT, D, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fjb, Boer, K, Ehrnst, A, Bohlin, Ab, Lindgren, S, Anzen, B, Lidman, K, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Ferrazin, A, Viscoli, C, DE MARIA, A, Bentivoglio, G, Ferrero, S, Gotta, C, Mur, A, Paya, A, LOPEZ VILCHEZ MA, Carreras, R, Valerius, Nh, Rosenfeldt, V, Jimenez, J, Coll, O, Suy, A, Perez, Jm, Fortuny, C, Boguna, J, Caro, Mc, Canet, Y, Ravizza, M, Guerra, B, Lanari, M, Bianchi, S, Bovicelli, L, Prati, E, Duse, M, Scaravelli, G, Stegagno, M, DE SANTIS, M, Savasi, V, Fiore, S, Crivelli, M, Ferrazzi, E, Vigano, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Probizer, Fr, Maccabruni, A, Bucceri, A, Rancilio, L, Alberico, S, Rabusin, M, Bernardon, M, Taylor, Gp, Lyall, Egh, Penn, Z, Buffolano, W, Tiseo, R, Martinelli, A, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, C, Niemiec, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Malyuta, R, Semenenko, I, Pilipenko, T, Posokhova, S, Kaleeva, T, Stelmah, A, Kiseleva, G., European Collaborative Study, Patel D, Thorne C, Newell ML, Cortina-Borja M [, Guerra B, Lanari M ], Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Infectious diseases, Other Research, and Obstetrics and Gynaecology

Subjects
Microbiology (medical), Adult, medicine.medical_specialty, Race, Adolescent, Black People, Gestational Age, HIV Infections, Disease, White People, HIV, Pregnancy, HIV RNA viral load, ART-naïve, Young Adult, Asian People, pregnancy, Medicine, Humans, Young adult, Pregnancy Complications, Infectious, business.industry, Obstetrics, Confounding, RNA, Gestational age, General Medicine, Viral Load, medicine.disease, CD4 Lymphocyte Count, hiv, art-naïve, hiv rna viral load, race, art-naive, Infectious Diseases, Immunology, HIV-1, RNA, Viral, Female, Sample collection, business, Viral load
Abstract

Objective: To assess pregnancy levels and patterns of HIV RNA in the absence of antiretroviral therapy, while appropriately adjusting for potential confounders, including maternal immune status and race. Methods: Data on >= 1 antenatal HIV RNA measurements were available for 333 untreated HIV-infected pregnant women enrolled in the European Collaborative Study. CD4 counts and HIV RNA measurements were routinely collected from 1992 and 1998, respectively. Linear mixed effects models based on 246 women for whom complete data were available examined changes in HIV RNA levels over pregnancy, with a nested random effects term accounting for measurement variability within women and period of sample collection. Results: The change in HIV RNA over pregnancy varied significantly by race (p = 0.005): from the second trimester until delivery, HIV RNA decreased significantly by an estimated 0.019 log(10) copies/ml/week in white women (95% Cl -0.03, -0.007); in black women the estimated 0.016 log(10) copies/ml/week increase (95% Cl -0.005, 0.037) was not statistically significant. At delivery, HIV RNA levels in black women were 0.45 log(10) copies/ml higher (95% Cl 0.08, 0.83) than in white women. Conclusions: Our findings suggest that HIV RNA dynamics over pregnancy differ by race, although other interpretations cannot be excluded, due to potential for unmeasured confounding. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved

Full Text
View/download PDF

139. Synthesis and x-ray characterization of the [Ir6(CO)15COEt]-Anionic Cluster

Author

Mario Manassero, Mirella Sansoni, Secondo Martinengo, Luigi Garlaschelli, Francesco Demartin, and Raimondi C. Carlo

Subjects
Ethylene, Chemistry, Organic Chemistry, X-ray, chemistry.chemical_element, Photochemistry, Biochemistry, Ion, Rhodium, Inorganic Chemistry, chemistry.chemical_compound, Crystallography, Octahedron, Materials Chemistry, Cluster (physics), Iridium, Physical and Theoretical Chemistry, Acyl group
Abstract

The reaction of Ir 6 (CO) 16 with a mixture of CO, H 2 , and ethylene yields the [Ir 6 (CO) 15 COEt] - anion, which has been shown by X-ray diffraction to contain an octahedral iridium cluster bearing a —bonded acyl group; the arrangement of the 11 terminal and 4 edge-bridging carbonyl groups is different from that found in both the analogous rhodium complex and the parent Ir 6 (CO) 16 carbonyl.

Published
1983

140. Effects of Defibrotide in Acute Renal Failure due to Thrombotic Microangiopathy

Author

Vangelista, A., Frascà, G.M., Raimondi, C., Liviano-D’Arcangelo, G., and Bonomini, V.

Abstract

Thrombotic microangiopathy (TMA) can occur whenever pathogenetic events lead to fibrin deposition in the microcirculation. It has been suggested that intravascular coagulation is important in the development of renal as well as cerebral lesions. The mortality rate in adults varies from 50 to 70%; chronic or progressive renal failure occurs in approximately two thirds of children over 2 years of age. Poor success may be due to therapy being initiated too late or to inappropriate use of antagonistic drugs, or both. In the last 2 years we have treated 8 patients with TMA (5 with thrombotic thrombocytopenic purpura; 3 with hemolytic uremic syndrome) with defibrotide, a new antithrombotic agent extracted from mammalian lungs. At admission all patients had severe renal involvement (serum creatinine 5.3–14.9 mg/dl) and coagulation abnormalities (low platelet count; high levels of circulating fibrin degradation products). There were neurological manifestations in 6 patients. Defibrotide administration was followed in 6 patients by recovery of renal function.In all patients, defibrotide therapy induced the disappearance of neurological manifestations and normalization of coagulation abnormalities. Defibrotide caused no side effects. All patients are alive after 7–22 months of follow-up.

Published
1986
Full Text
View/download PDF

141. [Role of loco-regional treatments for patients with breast cancer liver metastases]

Author

Raimondi, C, Danova, M, Chatzileontiadou, S, Vercelli, A, PALMERI, Laura, PALMERI, Sergio, Raimondi, C, Danova, M, Chatzileontiadou, S, Palmeri, L, Vercelli, A, and Palmeri, S

Subjects
Settore MED/06 - Oncologia Medica, liver metastases from breast cancer,hepatic resection,loco-regional treatment, radio-frequency ablation

144. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis

Author

Stefoni, S., Cianciolo, G., Gabriele DONATI, Colì, L., La Manna, G., Raimondi, C., Dalmastri, V., Orlandi, V., and D Addio, F.

Subjects
Male, Cross-Over Studies, Heparin, Antithrombin III, Anticoagulants, Hemodiafiltration, Heparin, Low-Molecular-Weight, Middle Aged, Platelet Activation, Platelet Factor 4, beta-Thromboglobulin, Lipids, Renal Dialysis, Factor Xa, Humans, Kidney Failure, Chronic, Female, Partial Thromboplastin Time, Blood Coagulation, Aged, Factor Xa Inhibitors, Fibrinopeptide A, Peptide Hydrolases
Abstract

To compare standard heparin (SH) and low molecular weight heparin (LMWH) in terms of anticoagulation, platelet activation and lipid metabolism, we selected 54 patients who had been on 4-hour hemodialysis three times weekly for at least 12 months, without bleeding disorders or dyslipidemic diseases. 28 were on hemodialysis with Polysulfone low-flux, 26 were on hemodiafiltration with Polysulfone high-flux. All patients underwent EPO.During the first 18 months, we administered SH 1,500 IU on starting dialysis and 1,500 +/- 500 IU in continuous intradialytic infusion per session. In the following 18 months, we administered LMWH 64.6 IU/kg on starting dialysis in a single arterious bolus. We assessed aPTT, anti-factor Xa activity, TAT and FPA, beta-TG and PF4. Blood samples were taken monthly at times 0, 30, 60, 180 and 240 min, as well as 1, 4 and 20 h after dialysis end. Predialysis cholesterol, HDL, LDL, triglycerides and lipoprotein(a) were checked monthly.During both LMWH and SH sessions no clotting or major bleeding complications were observed. APTT with LMWH was lower than that found with SH (p0.001); aFXa using LMWH was higher than when using SH (p0.001); TAT and FPA were lower in LMWH sessions (p0.01) than in SH sessions. We also detected lower beta-TG (p0.05) and PF4 levels (p0.05) using LMWH than using SH. As regards lipids, we only observed a significant decrease in triglycerides after 18 months of LMWH treatment.Routine use of LMWH during hemodialysis affords a safe and effective alternative to SH, and causes reduced platelet activation.

Catalog

Books, media, physical & digital resources
See catalog results